ArticleJournal of clinical & cellular immunology2013
Intranasal Delivery of Neural Stem Cells: A CNS-specific, Non-invasive Cell-based Therapy for Experimental Autoimmune Encephalomyelitis.
Article in Journal of clinical & cellular immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 49 citations in OpenAlex.
- Oligodendrocyte precursor cell-derived exosomes combined with cell therapy promote clinical recovery by immunomodulation and gliosis attenuation.Frontiers in cellular neuroscience · 2024Article
- Review
- Article
- Nose-to-Brain: The Next Step for Stem Cell and Biomaterial Therapy in Neurological Disorders.Cells · 2022Review
- Intranasally applied human olfactory mucosa neural progenitor cells migrate to damaged brain regions.Future science OA · 2022Article
- Evaluation of Recent Intranasal Drug Delivery Systems to the Central Nervous System.Pharmaceutics · 2022Review
- Human nasal olfactory stem cells, purified as advanced therapy medicinal products, improve neuronal differentiation.Frontiers in neuroscience · 2022Article
- Characterization of focused ultrasound-mediated brainstem delivery of intranasally administered agents.Journal of controlled release : official journal of the Controlled Release Society · 2020Article
- Cell motility and migration as determinants of stem cell efficacy.EBioMedicine · 2020Article
- Review
- Neural Stem Cell-Based Regenerative Approaches for the Treatment of Multiple Sclerosis.Molecular neurobiology · 2018Review
- The Route by Which Intranasally Delivered Stem Cells Enter the Central Nervous System.Cell transplantation · 2018Article
- Grafting Neural Stem and Progenitor Cells Into the Hippocampus of Juvenile, Irradiated Mice Normalizes Behavior Deficits.Frontiers in neurology · 2018Article
- Photodynamic opening of blood-brain barrier.Biomedical optics express · 2017Article
- Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease.Molecular neurobiology · 2017Article
- Novel drug-delivery approaches to the blood-brain barrier.Neuroscience bulletin · 2015Review
- Multiple Sclerosis and Experimental Allergic Encephalomyelitis.Journal of clinical & cellular immunology · 2013Article
- Blood brain barrier: An overview on strategies in drug delivery, realistic in vitro modeling and in vivo live tracking.Tissue barriersReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The therapeutic potential of adult neural stem cells (aNSCs) has been shown in EAE, an animal model of MS, administered by either i.c.v. or i.v. injection. However, i.c.v. is an invasive approach, while the i.v. route of aNSCs is associated with a non-specific immune suppression in the periphery. Here we demonstrate that intranasal (i.n.) delivery of fluorescently labeled aNSCs resulted in their appearance in the olfactory bulb, cortex, hippocampus, striatum, brainstem, and spinal cord. These cells induce functional recovery from ongoing EAE similar to that achieved with i.v. injected aNSCs, with comparable anti-inflammatory and remeylination effects in CNS inflammatory foci. Importantly, unlike the peripheral immune suppression brought about by i.v. NSCs, intranasal delivery did not influence peripheral immune responses. We conclude that aNSCs can be reliably delivered to the CNS via the nasal route to induce functional recovery and confer immunomodulation and remyelination in EAE. Intranasal administration of NSCs provides a highly promising, noninvasive and CNS-specific alternative to current cell-based approaches in treating EAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.